Simulations Plus, Inc. is a developer of drug discovery and development software for mechanistic modeling and simulation, for machine-learning-based prediction of properties of molecules solely from their structure, and is exploring the application of its machine-learning technologies in other industries, including aerospace/military and general healthcare. The Company provides specific proprietary software products, such as GastroPlus, a physiologically-based simulation tool that predicts the absorption, pharmacokinetics, pharmacodynamics, and drug-drug interactions for compounds administered through intravenous, oral, ocular, or pulmonary routes; ADMET Predictor, an ADME-Tox property prediction, and model building application; MedChem Studio, a multi-purpose cheminformatics platform used for advanced data mining and de novo molecule design; DDDPlus, a simulation program for formulation scientists that predicts the in vitro disintegration and dissolution of solid dosage forms under different experimental conditions; MedChem Designer, a free chemical sketching product that combines innovative molecule drawing features with fast and accurate ADMET property predictions from ADMET Predictor.
Company Growth (employees)
Simulations Plus Office Locations
Simulations Plus Data and Metrics
Simulations Plus Financial Metrics
Revenue (Y, 2016) | 20 m |
Revenue growth (Y, 2015 - Y, 2016), % | 9% |
Gross profit (Y, 2016) | 15.4 m |
Gross profit margin (Y, 2016), % | 77% |
Net income (Y, 2016) | 5 m |
EBIT (Y, 2016) | 7.2 m |
Market capitalization (21-Jun-2017) | 207.7 m |
Closing share price (21-Jun-2017) | 12 |
Cash (31-Aug-2016) | 8 m |
| Numbers are in $, USD | Y, 2014 | Y, 2015 | Y, 2016 |
|---|---|---|---|
Revenue | 11.5 m | 18.3 m | 20 m |
Revenue growth, % | 60% | 9% | |
Cost of goods sold | 1.6 m | 4.3 m | 4.6 m |
Gross profit | 9.8 m | 14 m | 15.4 m |
Gross profit Margin, % | 86% | 76% | 77% |
Operating expense total | 5.4 m | 8.1 m | 8.1 m |
EBIT | 4.4 m | 5.9 m | 7.2 m |
EBIT margin, % | 39% | 32% | 36% |
Interest income | 31.4 k | 17.9 k | 18 k |
Pre tax profit | 4.5 m | ||
Income tax expense | (1.5 m) | (1.8 m) | (2.3 m) |
Net Income | 3 m | 3.8 m | 5 m |
| Numbers are in $, USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Cash | 8.6 m | 8.6 m | 8 m | |
Inventories | 188.2 k | 381.7 k | 410.8 k | |
Current Assets | 11.5 m | 11.5 m | 12.9 m | |
PP&E | 95.2 k | 413.5 k | 256.4 k | |
Goodwill | 4.8 m | 4.8 m | ||
Total Assets | 21 m | 27.3 m | 28 m | |
Accounts Payable | 130.5 k | 209.4 k | 108.1 k | |
Current Liabilities | 1.4 m | 3.6 m | 2.1 m | |
Additional Paid-in Capital | 6.1 m | 9.7 m | 11.4 m | |
Retained Earnings | 9.3 m | 9.8 m | 11.3 m | |
Total Equity | 15.4 m | 19.5 m | 22.7 m | |
Financial Leverage | 1.4 x | 1.4 x | 1.2 x |
| Numbers are in $, USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Net Income | 3 m | 3.8 m | 5 m | |
Accounts Receivable | 1 m | (1.4 m) | ||
Inventories | 192.2 k | |||
Accounts Payable | 146 k | (15.5 k) | 19.4 k | (101.3 k) |
Cash From Operating Activities | 5.3 m | 7.1 m | 5.4 m | |
Purchases of PP&E | (24.5 k) | (71.4 k) | (39.1 k) | |
Cash From Investing Activities | (3.9 m) | (3.1 m) | (2 m) | |
Income Taxes Paid | 692.6 k | 961.9 k | 2.9 m |
| Numbers are in $, USD | Y, 2016 |
|---|---|
Revenue/Employee | 350.4 k |
Financial Leverage | 1.2 x |
